Apr 14, 2016 - The Allergan stock price has dropped 20% since the deal with Pfizer collapsed.Despite this, the stock is still very expensive.But Allergan is a company with many admirable qualities.
Apr 14, 2016 - Long/Short Investments posits Allergan may be overvalued by P/E, EV/EBITDA, and EV/Revenue. I'll argue the limitations of these metrics when applied to Allergan in its current state. By relying too mu
Apr 14, 2016 - Is the CI – ANTM merger still on in light of the new tax laws?The CI and ANTM merger is quite different from that of the PFE and AGN merger.I give my suggestion for playing the merger.
Apr 14, 2016 - VRX & MNK Should consider merging.It would be a win-win for all parties involved.A combined company under new leadership could thrive in the specialty pharmaceuticals market.
Apr 13, 2016 - The biotech sector has held up well over the past few days as it consolidates gains made over the past two weeks.Possible increased M&A activity thanks to large tax inversion deals being off the table
Apr 13, 2016 - My portfolio is beating the market 6.34% to a drop of 1.64%. I added additional shares of Allergan to the portfolio today. Eaton Vance, Priceline, and McGraw-Hill are buoying the losses Allergan has c
Apr 12, 2016 - Allergan has dipped into the high $220s, or off approximately 30% from its 52-week high.Allergan's projected 2016 EPS and forward-looking P/E multiple may justify a price in its current range in the s
Apr 12, 2016 - After nearly a decade of delays Allergy Therapeutics (NYSE:AGN) is getting back on track with its short-course allergy vaccines. The company expects results from two phase II studies at the end of Jun
Apr 11, 2016 - The main M&A story so far this year was the one that got away: the collapse of Pfizer’s (NYSE:PFE) purchase of Allergan (NYSE:AGN). But a closer look at M&A activity in the first quarter uncov
Apr 11, 2016 - Pfizer has serious Revenue Diversity in its Product Portfolio. But nearly 35% Sales are from Products that are off-patent or soon will be. Total Sales have declined in recent years. Despite this, Ibra